Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionClosed to enrollment Location: Multicentre

    A Phase 3 Study of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor , protocol number NCT02412111 VX14-661-109

    This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study in subjects aged 12 years and older with CF who are heterozygous for the F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive.

    • Age:

      12 years and older

    • Mutation(s):

      Heterozygous for F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive

    • FEV1% Predicted:

      FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Australia

    A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation , protocol number NCT02730208 VX15-661-112

    A Phase 2, Randomized, Placebo-Controlled, Double-blind Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    • Age:

      >12 years

    • Mutation(s):

      Homozygous for the F508del CFTR mutation

    • FEV1% Predicted:

      ppFEV1 ≥70% of predicted normal

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Australia

    A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation , protocol number NCT02875366 VX15-809-112

    A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

    • Age:

      >12 years

    • Mutation(s):

      Homozygous F508del

    • FEV1% Predicted:

      FEV1 at least 40% and not greater than 90% of predicted.

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Australia

    A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation , protocol number NCT02742519 VX15-770-123

    A Phase 3b, 2-part, Randomized, Double-blind, Placebo-controlled Crossover Study With a Long-term Open-label Period to Investigate Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

    • Age:

      3-5 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: NSW - Australia

    Randomised controlled trial to be determine whether once-daily insulin detemir slows decline in weight and lung functions in patients with cystic fibrosis and early insulin deficiency. , protocol number ACTRN13611000068965 NCT01100892

    Cystic fibrosis (CF) is the most common life-threatening genetic condition affecting Australian children. As well as repeated lung infections, children with CF develop insulin deficiency and eventually diabetes. The CF-IDEA trial (Cystic Fibrosis - Insulin Deficiency, Early Action) will determine whether starting insulin treatment before the onset of diabetes (earlier than current practice) will improve the health of children with CF by improving body weight and lung function.

    • Age:

      5 Years to 19 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Australia

    Continuous infusion antipseudomonal betalactams versus standard short infusions in the treatment of acute infective exacerbations in patients with cystic fibrosis - impact on clinical and microbiological outcomes. , protocol number ACTRN12612000945820 NCT01667094

    Cystic fibrosis (CF) is an inherited disorder which results in increased thickness of secretions, especially in the lungs. By adulthood, the majority of patients with CF will have bacteria living in their lungs, called Pseudomonas which can cause lung infections. This usually results in worsening respiratory symptoms and often an acute deterioration in their lung function. They are usually treated with antibiotics that target the Pseudomonas aeruginosa. These antibiotics are typically given as short intravenous infusions several times a day. This study aims to compare the standard method of giving these antibiotics with a different strategy of giving these antibiotics to see if this can improve the outcomes of treatment of these infections and reduce the amount of Pseudomonas aeruginosa in the lungs of these patients. This strategy consists of giving the same antibiotics continuously, to ensure there is always enough antibiotic in the bloodstream and the lung to be able to kill the bacteria.

    • Age:

      18 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Australia

    The Alfred Step Test Exercise Protocols (A-STEP and A-STEPmax): Developed for Adults With Cystic Fibrosis (A-STEP/max) , protocol number NCT02717650

    Feasibility and Validation of the Alfred Step Test Exercise Protocols (A-STEP and A-STEPmax): Developed to Assess Exercise Tolerance and Determine Maximum Oxygen Uptake in Adults With Cystic Fibrosis Across the Disease Spectrum

    • Age:

      >18 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      FEV1 greater than 20%

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherActive, not recruiting Location: Australia, Melbourne

    CPET in CF patients with one G551D mutation taking VX770 , protocol number NCT01937325

    Double-blind, placebo-controlled cross-over study of 20 patients currently awaiting initiation of ivacaftor therapy.

    • Age:

      16-70 years

    • Mutation(s):

      Hetrozygous G551D

    • FEV1% Predicted:

      > 25%

    • Number of Visits:

      Not specified

    • Length of Participation:

      224 days

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Australia, Melbourne

    The Prevalence and Significance of Gastro-oesophageal Reflux in Adults With Cystic Fibrosis Before and After Lung Transplantation, Together With the Effects of Physiotherapy Airway Clearance Techniques on Gastro-oesophageal Function , protocol number NCT00164021 NCT00164021

    A factorial longitudinal study will be undertaken in adults with cystic fibrosis. Results will be compared with age matched healthy controls. It is not deemed appropriate to randomise patients with gastro-oesophageal reflux(GOR) to a treatment versus no treatment group as immediate treatment for GOR once diagnosed is regarded as obligatory. Subjects: 180 adults with CF will be recruited from the Adult Cystic Fibrosis Unit at the Alfred Hospital to participate in the study. The ambulatory studies will be undertaken during baseline state in the outpatient setting. Fifteen age matched control subjects will be recruited from the general population.

    • Age:

      16-70 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 3 study of long-term ivacaftor in babies who have a CFTR gating mutation , protocol number NCT03277196 VX-770-126

    This open-label study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of long-term ivacaftor in babies who have a CFTR gating mutation.

    • Age:

      0 days to 24 months

    • Mutation(s):

      One copy F508del or no copies F508del

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      18

    • Length of Participation:

      128 weeks

    Contact us about this clinical Trial >
  • Displaying results 11-20 (of 142)
     |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|